Curve Biosciences, a biotechnology company pioneering Whole-Body Intelligence for proactive and personalized chronic disease care, has raised $40 million in new funding led by Luma Group, with participation from First Spark Ventures, Techas Capital, Micah Spear, Civilization Ventures, LifeX Ventures, Incite, Mintaka VC, NZVC, and others.
The capital will accelerate the clinical validation and commercialization of Curve’s Whole-Body Intelligence platform, a data-driven system designed to transform how chronic diseases are detected, monitored, and managed. The company aims to empower healthcare providers, insurers, and patients to predict and prevent chronic conditions before they progress, reducing overall healthcare costs and improving patient outcomes.
Curve’s proprietary Whole-Body Atlas serves as the foundation of its approach. The Atlas represents the world’s most extensive manually curated collection of tissue samples categorized by organ type and disease state, providing a deep molecular understanding of the human body. Built from this biological reference, the company’s Whole-Body Blood Tests are designed to detect chronic disease signatures earlier and more accurately than conventional diagnostics. By returning to tissue-level biology, Curve is building a new standard in precision medicine, enabling proactive care tailored to each patient.
The company’s new funding also supports the expansion of its AI-driven platform, which integrates biological data and machine learning to identify disease patterns and treatment responses. Curve’s models are trained on data from the Whole-Body Atlas. They are designed to align patients, physicians, pharmaceutical companies, and payers around a shared, data-rich view of human health.
Curve’s leadership team brings together experienced executives from the life sciences and diagnostics sectors. The team includes CEO and Co-Founder Ritish Patnaik, PhD (formerly of Genentech), Chief Scientific Officer Nathan Hunkapiller, PhD (previously Head of R&D at both Natera and GRAIL), Chief Operating Officer Alice Chen, PhD (former Head of Product and Program Management at GRAIL), Chief Technology Officer Chuba Oyolu, PhD (Founding Scientist and Senior Site Director at Counsyl), and Chief Innovation Officer and Scientific Founder Professor Shan Wang, PhD, of Stanford University.
This executive group is driving the development of Curve’s Whole-Body Intelligence platform and building a pipeline of tests targeting primary chronic conditions. The company expects to share further details on its upcoming diagnostic programs and commercial launch timeline in the coming months.
KEY QUOTES:
“Chronic diseases are on the rise, and healthcare costs are skyrocketing as a result. We need to improve patient monitoring to realize the positive impacts of breakthroughs like GLP-1s. To raise the standard of chronic disease monitoring, we are now introducing the first Whole-Body Intelligence platform with AI models trained on our Whole-Body Atlas and fueled by our Whole-Body Blood Tests. We’ve paired this platform with a successful executive team to realize our vision for proactive, personalized chronic care that minimizes suffering.”
Ritish Patnaik, PhD, Chief Executive Officer and Co-Founder, Curve Biosciences
“We believe Curve’s Whole-Body Intelligence platform represents the next frontier in clinical testing, with the potential to fundamentally reshape how we monitor and manage chronic disease. By anchoring in human tissue data, Curve is building a clinically actionable platform with clear reimbursement potential and massive market applicability.”
Themasap Khan, PhD, Co-Founder and Partner, Luma Group
